Nobel Prize / Paleogenetic Pioneer Wins 2022 Award
Svante Paabo has won the 2022 Nobel Prize in physiology or medicine for his ground-breaking work in paleogenetics. Paabo’s research – which includes sequencing the genome of the Neanderthal for…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain components, including manufacturing, to independent CDMOs. In Europe the CDMO…
Svante Paabo has won the 2022 Nobel Prize in physiology or medicine for his ground-breaking work in paleogenetics. Paabo’s research – which includes sequencing the genome of the Neanderthal for…
Sweden is fast staking a claim as one of Europe’s premier biotech hotspots thanks to a holistic approach to research projects, a strong institutional ecosystem, and increasingly easy access to…
Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real…
Belying its small size, the Nordic nation of Sweden punches well above its weight in scientific innovation. Despite boasting a population of just 10 million and a marginal position on…
Anders Blanck of Lif, the trade association for the research-based Swedish pharmaceutical industry, outlines the steps already being put in place for Sweden to become a leading country in the…
Anders Blanck, CEO of Lif, the trade association for the research-based Swedish pharmaceutical industry, writes about the challenges the world faces from antimicrobial resistance (AMR). Sweden has for decades been…
Anders Blanck, CEO of LIF, the industry organisation for the research-based pharmaceutical industry in Sweden, describes the Sustainability Strategy that the pharma industry in Sweden is now launching. Central to…
Since going public five years ago, Recipharm, Sweden’s iconic indigenous contract development and manufacturing organization (CDMO), has seen its sales skyrocket by over 30 percent annually. Much of this growth…
The recent FDA decision to investigate the serious risk of patients developing new cancers after treatment with CAR-T therapies may have created some bad press around cell and gene therapies,…
See our Cookie Privacy Policy Here